DOCSLIB.ORG

Drug Tariff Part VIIIA August 2021.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Tariff Part VIIIA August 2021.Pdf 08/2021 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Part VIIIA - Basic Prices of Drugs Product List Part VIIIA products A Abacavir 600mg / Lamivudine 30 19000 C Lupin Healthcare 300mg tablets (UK) Ltd Abatacept 125mg/1ml solution for 4 120960 C Orencia ClickJect injection pre-filled disposable devices Abatacept 125mg/1ml solution for 4 120960 C Orencia injection pre-filled syringes Acacia spray dried powder 250 g 1632 C J M Loveridge Ltd Acamprosate 333mg gastro- 168 3825 A resistant tablets Acarbose 100mg tablets 90 2529 A Acarbose 50mg tablets 90 1458 A Acebutolol 100mg capsules 84 1497 C Sectral Acebutolol 200mg capsules 56 1918 C Sectral Acebutolol 400mg tablets 28 1862 C Sectral Aceclofenac 100mg tablets 60 598 L A Acenocoumarol 1mg tablets 100 462 C Sinthrome Acetazolamide 250mg modified- 30 1666 C Diamox SR release capsules Acetazolamide 250mg tablets 112 663 M Acetic acid 2% ear spray S 5ml 410 C EarCalm Acetone liquid 50 ml 128 L A Acetylcysteine 200mg oral powder 30 11250 A sachets sugar free Acetylcysteine 2g/10ml solution for 10 2126 C Martindale infusion ampoules Pharmaceuticals Ltd Acetylcysteine 5% eye drops S 10 ml 3647 C Ilube Acetylcysteine 600mg capsules 30 5720 K A Acetylcysteine 600mg effervescent 30 550 C tablets sugar free (2xS15) Aciclovir 200mg dispersible tablets 25 182 A Aciclovir 200mg tablets 25 163 M Aciclovir 200mg/5ml oral 125 ml 3578 A suspension sugar free Aciclovir 3% eye ointment S 4.5 g 4500 C Agepha Pharma s.r.o. Aciclovir 400mg dispersible tablets 56 1199 A Aciclovir 400mg tablets 56 325 M Aciclovir 400mg/5ml oral 100 ml 3949 A suspension sugar free Aciclovir 5% cream S 2g 135 A S 10 g 677 A Aciclovir 800mg dispersible tablets 35 1099 A Aciclovir 800mg tablets 35 397 M Acipimox 250mg capsules 90 4633 C Olbetam Acitretin 10mg capsules 60 2761 L A Acitretin 25mg capsules 60 4375 A Aclidinium bromide 375micrograms/ S 60 dose 3250 C Eklira dose dry powder inhaler 225 08/2021 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Aclidinium bromide 396micrograms/ S 60 dose 3250 C Duaklir Genuair dose / Formoterol 11.8micrograms/dose dry powder inhaler Acrivastine 8mg capsules 12 320 C Benadryl Allergy Relief Activated charcoal 200mg/ml oral S 250 ml 1188 C Charcodote suspension sugar free Activated charcoal 300mg tablets 100 247 C J.L. Bragg's Medicinal Charcoal Adalimumab 20mg/0.2ml solution 2 35214 C Humira for injection pre-filled syringes Adalimumab 40mg/0.4ml solution 2 70428 C Humira for injection pre-filled disposable devices Adalimumab 40mg/0.4ml solution 2 70428 C Humira for injection pre-filled syringes Adapalene 0.1% / Benzoyl peroxide S 45 g 1953 C Epiduo 2.5% gel Adapalene 0.1% cream S 45 g 1643 C Differin Adapalene 0.1% gel S 45 g 1643 C Differin Adapalene 0.3% / Benzoyl peroxide S 45 g 1953 C Epiduo 2.5% gel Adefovir 10mg tablets S 30 25222 C Hepsera Adrenaline (base) 100micrograms/ 10 9259 C Martindale 1ml (1 in 10,000) dilute solution Pharmaceuticals Ltd for injection ampoules Adrenaline (base) 10mg/10ml (1 in 10 11132 C Martindale 1,000) solution for injection Pharmaceuticals Ltd ampoules Adrenaline (base) 150micrograms/ S 13430CJext 0.15ml (1 in 1,000) solution for injection pre-filled disposable devices Adrenaline (base) 150micrograms/ S 13430CEpiPen Jr. 0.3ml (1 in 2,000) solution for injection pre-filled disposable devices 26860CEpiPen Jr. Adrenaline (base) 1mg/1ml (1 in 10 1034 A 1,000) solution for injection ampoules Adrenaline (base) 1mg/1ml (1 in S 11347A 1,000) solution for injection pre-filled syringes Adrenaline (base) 300micrograms/ S 13430C 0.3ml (1 in 1,000) solution for injection pre-filled disposable devices Adrenaline (base) 500micrograms/ 10 9306 A 0.5ml (1 in 1,000) solution for injection ampoules 226 08/2021 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Adrenaline (base) 500micrograms/ S 12699CEmerade 0.5ml (1 in 1,000) solution for injection pre-filled disposable devices Adrenaline (base) 500micrograms/ 10 9864 C Martindale 5ml (1 in 10,000) dilute solution Pharmaceuticals Ltd for injection ampoules Adrenaline (base) 5mg/5ml (1 in 10 11349 C Martindale 1,000) solution for injection Pharmaceuticals Ltd ampoules Agomelatine 25mg tablets 28 2298 L A Alclometasone 0.05% cream S 50 g 1687 K A Alendronic acid 10mg tablets 28 648 M Alendronic acid 70mg / S 4425CBentexo Colecalciferol 140microgram tablets Alendronic acid 70mg / S 42280CFosavance Colecalciferol 70microgram tablets Alendronic acid 70mg effervescent S 41160L C Binosto tablets sugar free Alendronic acid 70mg tablets S 490M Alendronic acid 70mg/100ml oral 42858A solution unit dose sugar free Alfacalcidol 1microgram capsules S 30 441 M Alfacalcidol 1micrograms/0.5ml 10 2157 C One-Alpha solution for injection ampoules Alfacalcidol 250nanogram capsules S 30 493 A Alfacalcidol 2micrograms/1ml 10 4113 C One-Alpha solution for injection ampoules Alfacalcidol 2micrograms/ml oral S 10 ml 2130 C One-Alpha drops sugar free Alfacalcidol 500nanogram capsules S 30 990 A Alfentanil 1mg/2ml solution for 10 634 C Rapifen injection ampoules Alfentanil 5mg/10ml solution for 51600CRapifen injection ampoules 10 2980 C hameln pharma Ltd Alfentanil 5mg/1ml solution for 10 2319 C Rapifen Intensive injection ampoules Care Alfuzosin 10mg modified-release 30 1251 C tablets Alfuzosin 2.5mg tablets 60 159 M Alginate raft-forming oral 150 ml 258 C Gaviscon Original suspension sugar free Aniseed Relief 300 ml 433 C Gaviscon Original Aniseed Relief 500 ml 195 C Peptac liquid 600 ml 711 C Gaviscon Original Aniseed Relief Alimemazine 10mg tablets 28 11288 A Alimemazine 30mg/5ml oral 100 ml 24351 A solution 227 08/2021 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category Alimemazine 7.5mg/5ml oral 100 ml 17958 A solution Alirocumab 150mg/1ml solution for 2 33600 C Praluent injection pre-filled disposable devices Alirocumab 75mg/1ml solution for 2 33600 C Praluent injection pre-filled disposable devices Aliskiren 150mg tablets 28 2851 C Rasilez Aliskiren 300mg tablets 28 3427 C Rasilez Alitretinoin 10mg capsules 30 49372 C Toctino Alitretinoin 30mg capsules 30 49372 C Toctino Allantoin 0.5% / Lidocaine 0.5% S 25 g 303 C Anodesyn ointment Allantoin 10.25mg / Lidocaine 12 311 C Anodesyn 10.25mg suppositories Allopurinol 100mg tablets 28 106 M Allopurinol 300mg tablets 28 154 M Almotriptan 12.5mg tablets 3 816 L A 61632L A 92448L A Alogliptin 12.5mg / Metformin 1g 56 2660 C Vipdomet tablets Alogliptin 12.5mg tablets 28 2660 C Vipidia Alogliptin 25mg tablets 28 2660 C Vipidia Alogliptin 6.25mg tablets 28 2660 C Vipidia Alpha tocopheryl acetate 500mg/ 100 ml 6967 K C Alliance 5ml oral suspension Pharmaceuticals Ltd § Alprostadil 10microgram powder S 21655CViridal Duo and solvent for solution for Continuation Pack injection cartridges § Alprostadil 10microgram powder S 22013CViridal Duo Starter and solvent for solution for Pack injection cartridges with device § Alprostadil 10microgram powder 21470CCaverject Dual and solvent for solution for Chamber injection pre-filled disposable devices § Alprostadil 10microgram powder S 1924CCaverject and solvent for solution for injection vials § Alprostadil 1mg urethral sticks S 11156CMuse § Alprostadil 20microgram powder S 22139CViridal Duo and solvent for solution for Continuation Pack injection cartridges § Alprostadil 20microgram powder S 22454CViridal Duo Starter and solvent for solution for Pack injection cartridges with device § Alprostadil 20microgram powder 21900CCaverject Dual and solvent for solution for Chamber injection pre-filled disposable devices 228 08/2021 Part VIIIA BASIC PRICES OF DRUGS Drug Quantity Basic Price Category § Alprostadil 20microgram powder S 11194CCaverject and solvent for solution for injection vials § Alprostadil 3mg/g cream 4 4000 C Vitaros § Alprostadil 40microgram powder S 22722CViridal Duo and solvent for solution for Continuation Pack injection cartridges § Alprostadil 40microgram powder S 22983CViridal Duo Starter and solvent for solution for Pack injection cartridges with device § Alprostadil 40microgram powder S 12158CCaverject and solvent for solution for injection vials § Alprostadil 500microgram urethral S 11130CMuse sticks Alum powder 500 g 672 C J M Loveridge Ltd Aluminium chloride 20% solution S 20 ml 395 C Driclor S 60 ml 251 C Anhydrol Forte Aluminium chloride 20% spray S 30 ml 733 C Odaban Alverine 120mg capsules 60 642 M Alverine 60mg / Simeticone 300mg 90 1100 C SimAlvia capsules Alverine 60mg capsules 100 615 M Amantadine 100mg capsules 56 2260 M Amantadine 50mg/5ml oral solution 150 ml 14000 K C Northumbria Pharma sugar free Ltd Ambrisentan 10mg tablets 30 161808 C Ambrisentan 5mg tablets 30 161808 C Amiloride 5mg / Bumetanide 1mg 28 5600 A tablets Amiloride 5mg tablets 28 3036 M Amiloride 5mg/5ml oral solution 150 ml 4645 A sugar free Aminophylline 250mg/10ml solution 10 1078 C hameln pharma Ltd for injection ampoules Aminophylline hydrate 350mg 56 422 C Phyllocontin Forte modified-release tablets Continus Aminosalicylic acid gastro-resistant 30 33100 C Granupas granules 4g sachets sugar free Amiodarone 100mg tablets 28 192 L A Amiodarone 200mg tablets 28 227 M Amiodarone 300mg/10ml solution S 11541A for injection pre-filled syringes Amisulpride 100mg tablets 60 540 M Amisulpride 100mg/ml oral solution S 60 ml 10445 L A sugar free Amisulpride 200mg tablets 60 797 M Amisulpride 400mg tablets 60 4208 A Amisulpride 50mg tablets 60 298 M Amitriptyline 10mg tablets 28 97 M Amitriptyline 10mg/5ml oral solution 150 ml 13647 A sugar free 229 08/2021 Part VIIIA BASIC PRICES
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Northern Ireland Prescription Code Book Drugs Section September 2021
    Family Practitioner Services, Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ Telephone No. 028 9053 5613, Fax No. 028 9053 2963 Northern Ireland Prescription Code Book Drugs section September 2021 Page 1 of 587 Effective for prescriptions dispensed September 2021 BSO Code dm+d Pack Description Code Number Special ZD Of Container 38960 4SURE beta-ketone testing strips 4S-810-4183401-001 (Nipro Diagnostics (UK) Ltd) 10 strip strips 38961 4SURE testing strips (Nipro Diagnostics (UK) Ltd) 50 strip strips 4144 AAA 1.5mg/dose sore throat spray (Manx Healthcare Ltd) 60 dose [BSO pack = 1] BSO Unit Of Measure Code No. devices dispensed 70598 (DT) Abacavir 600mg / Lamivudine 300mg tablets 30 tablet tablets 9154 Abasaglar 100units/ml solution for injection 3ml cartridges (Eli Lilly and Company Ltd) 5 cartridge cartridges ZD 9038 Abasaglar KwikPen 100units/ml solution for injection 3ml pre-filled pens (Eli Lilly and Company Ltd) 5 pre- injections ZD filled disposable injection 70088 (DT) Abatacept 125mg/1ml solution for injection pre-filled disposable devices 4 pre-filled disposable injections ZD injection 70089 (DT) Abatacept 125mg/1ml solution for injection pre-filled syringes 4 pre-filled disposable injection injections ZD 70144 Abelcet 100mg/20ml concentrate for suspension for infusion vials (Teva UK Ltd) 10 vial vials Hospital Only 3303 Abidec Multivitamin drops (Omega Pharma Ltd) 25 ml mls 4043 Abilify 10mg orodispersible tablets (Otsuka Pharmaceuticals (U.K.) Ltd) 28 tablet 4 x 7 tablets tablets 3006 Abilify 10mg tablets (Otsuka
    [Show full text]
  • 209627Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 209627Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review Reviewers of Multi-Disciplinary Review and Evaluation SECTIONS OFFICE/ AUTHORED/ ACKNOWLEDGED/ DISCIPLINE REVIEWER DIVISION APPROVED Mark Seggel, Ph.D. OPQ/ONDP/DNDP2 Authored: Section 4.2 Digitally signed by Mark R. Seggel -S CMC Lead DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Mark R. Signature: Mark R. Seggel -S Seggel -S, 0.9.2342.19200300.100.1.1=1300071539 Date: 2018.08.08 16:29:15 -04'00' Frederic Moulin, DVM, PhD OND/ODE3/DBRUP Authored: Section 5 Pharmacology/ Digitally signed by Frederic Moulin -S Toxicology DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Reviewer Signature: Frederic Moulin -S 0.9.2342.19200300.100.1.1=2001708658, cn=Frederic Moulin -S Date: 2018.08.08 15:26:57 -04'00' Kimberly Hatfield, PhD OND/ODE3/DBRUP Approved: Section 5 Pharmacology/ Toxicology Digitally signed by Kimberly P. Hatfield -S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, Team Leader Signature: Kimberly P. Hatfield -S 0.9.2342.19200300.100.1.1=1300387215, cn=Kimberly P. Hatfield -S Date: 2018.08.08 14:56:10 -04'00' Li Li, Ph.D. OCP/DCP3 Authored: Sections 6 and 17.3 Clinical Pharmacology Dig ta ly signed by Li Li S DN c=US o=U S Government ou=HHS ou=FDA ou=People Reviewer cn=Li Li S Signature: Li Li -S 0 9 2342 19200300 100 1 1=20005 08577 Date 2018 08 08 15 39 23 04'00' Doanh Tran, Ph.D.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Ophthalmic Antihistamines
    Ophthalmics for Allergic Conjunctivitis Review 04/12/2011 Copyright © 2004 - 2011 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 10101 Alliance Rd, Ste 201 Cincinnati, Ohio 45242 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein,
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • EAR, NOSE and OROPHARYNX Updated: October 2020
    Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY CHAPTER 12: EAR, NOSE AND OROPHARYNX Updated: October 2020 The following prescribing guidelines are relevant to the ENT chapter and can be found here: • Allergic Rhinitis in adults and adolescents over 12 years of age • Management of chronic rhinosinusitis with or without nasal polyps 12.1 DRUGS ACTING ON THE EAR 12.1.1 Otitis externa Investigation is not routinely recommended for the initial diagnosis of otitis externa. Group Drug Astringent/acidic Acetic acid 2% ear spray preparations Self-care: patients are advised to purchase this over the counter Gentamicin 0.3% ear/eye drops* Antibiotic preparations Ciprofloxacin 2mg/ml ear drops 0.25ml unit dose PF Betnesol-N ear/eye/ nose drops* Combined corticosteroid (Betamethasone 0.1% & neomycin 0.5%) and aminoglycoside Otomize ear spray* antibiotic preparations (Dexamethasone 0.1%, neomycin 0.5% & acetic acid 2%) Corticosteroid Prednisolone 0.5% ear/eye drops Lower potency preparations Betamethasone 0.1% ear/eye/ nose drops Higher potency Antifungal preparations Clotrimazole 1% solution 20ml (with dropper) * In view of reports of ototoxicity, manufacturers contra-indicate treatment with topical aminoglycosides in patients with a perforated tympanic membrane (eardrum) or patent grommet. 1. The following are GREY, not for first line empirical use, and should only be used when sensitivity is confirmed through swab results- • Hydrocortisone acetate 1%/gentamicin 0.3% ear drops • Flumetasone pivalate 0.02%/clioquinol 1% ear drops 2. How should I treat acute diffuse otitis externa? (CKS) • Remove or treat any precipitating or aggravating factors. • Prescribe or recommend a simple analgesic for symptomatic relief.
    [Show full text]
  • Minutes of PRAC Meeting on 09-12 July 2018
    6 September 2018 EMA/PRAC/576790/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 09-12 July 2018 Chair: June Raine – Vice-Chair: Almath Spooner Health and safety information In accordance with the Agency’s health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scope listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, the minutes are a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006, Rev. 1). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018.
    [Show full text]
  • Epinastine Hcl Ophthalmic Solution) 0.05% Sterile
    NDA 21-565/S-005 Page 2 ELESTAT™ (epinastine HCl ophthalmic solution) 0.05% Sterile DESCRIPTION ELESTAT™ (epinastine HCl ophthalmic solution) 0.05% is a clear, colorless, sterile isotonic solution containing epinastine HCl, an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes. Epinastine HCl is represented by the following structural formula: C16H15N3 • HCl Mol. Wt. 285.78 Chemical Name: 3-Amino-9, 13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine hydrochloride Each mL contains: Active: Epinastine HCl 0.05% (0.5 mg/mL) equivalent to epinastine 0.044% (0.44mg/mL); Preservative: Benzalkonium chloride 0.01%; Inactives: Edetate disodium; purified water; sodium chloride; sodium phosphate, monobasic; and sodium hydroxide and/or hydrochloric acid (to adjust the pH). ELESTAT™ has a pH of approximately 7 and an osmolality range of 250 to 310 mOsm/kg. CLINICAL PHARMACOLOGY Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine H2 receptor. Epinastine also possesses affinity for the α1-, α2-, and 5-HT2 –receptors. Epinastine does not penetrate the blood/brain barrier and, therefore, is not expected to induce side effects of the central nervous system. Fourteen subjects, with allergic conjunctivitis, received one drop of ELESTAT™ in each eye twice daily for seven days. On day seven average maximum epinastine plasma concentrations of 0.04 ± 0.014 ng/ml were reached after about two hours indicating low systemic exposure.
    [Show full text]
  • Ear, Nose and Oral Cavity
    NHS Borders Joint Prescribing Formulary Ear, nose, and oral cavity Black Text Drugs which may be prescribed by all prescribers Drugs which are either for specialist only prescription or for specialist Pink Text initiation, with prescribing transfer to GP Important Information: In addition to the disclaimer on NHS Borders website the following information is included confirming that the information contained in NHS Borders Joint Prescribing formulary is drawn from several sources, including BNF & BNF for children, product SPCs, local and national guidelines, local expert opinion, Lothian Joint Formulary and these are all gratefully acknowledged here. NHS Borders has done its utmost to ensure the information in the BJF is accurate and reliable, but NHS Borders cannot guarantee that the information is complete and accurate. Prescribers are referred to the SPCs, BNF and BNF for children to confirm prescribing information. June 2021 Contents Page Table of Contents 12.1 Drugs acting on the ear ................................................................................................ 3 Otitis externa ................................................................................................................ 3 Otitis media .................................................................................................................. 3 Removal of ear wax ..................................................................................................... 3 12.2 Drugs acting on the nose ............................................................................................
    [Show full text]
  • Allergy Skin Testing: Patient Instructions and Consent Form
    ALLERGY SKIN TESTING: PATIENT INSTRUCTIONS AND CONSENT FORM Skin tests are a method of testing for allergic reactions to substances, or allergens, in the environment. A test consists of introducing small amounts of allergens into the skin and noting the development of a positive reaction, which consists of a wheal (swelling) and flare (surrounding area of redness). We employ the prick method, where the skin is pricked with a sharp device that introduces the allergen into the skin. Other allergy testing options include injecting the allergen with needles or going to a lab for blood tests. The entire testing process will take about 30 minutes. We test a variety of important allergens that are found in the Central Florida area including trees, grasses, weeds, molds, dust mites, and animal dander. After administering the allergens, we wait approximately 20 minutes to review the results. A positive reaction occurs when the skin becomes red, raised, and itchy. This skin reaction will gradually dissipate within 30‐60 minutes. Some people will experience local swelling beginning 4‐8 hours after testing. This is not serious and typically no treatment is required. It should disappear in the next few days. Less than 1% of patients may develop a systemic reaction to skin testing, which may consist of any or all of the following symptoms: itchy eyes, nose, or throat, nasal congestion, runny nose, tightness in the throat or chest, wheezing, lightheadedness, nausea or vomiting, hives, or anaphylactic shock. This is very rare, but in the event of such reactions, the staff is fully prepared and emergency equipment is readily available.
    [Show full text]